FDA Approves Enlicitide, an Oral PCSK9 Inhibitor, for LDL-Lowering |…

The FDA has approved enlicitide (Lipfendra), the first oral PCSK9 inhibitor for LDL-lowering, as a once-daily alternative to existing injectable options from Amgen, Novartis, and Sanofi/Regeneron. The approval is based on phase III trial data showing 55–59% LDL reduction versus placebo, with comparable safety to injections. If you sell support tools, patient adherence software, or cost-management platforms into the PCSK9 market, your moat just shifted: oral pills scale faster than injections and will soon attract price-conscious payers who've held these drugs as premium-only. Merck's real win isn't the drug—it's the 14,500-patient outcomes trial that will either bury the other four PCSK9s or force them into combination therapy, turning you into a downstream dependency for whichever one survives.